Abstract: A functional structure which can resist a decrease in the function of the functional material and thus have a long life, can be free from the need for complicated replacement operation, can contribute to resource-saving, and can exhibit high catalytic activity when used, for example, as a catalyst. The functional structure includes supports each having porous structure and including a zeolite-type compound, and at least one functional substance present in the supports, in which each of the supports has channels communicating with one another, the functional material is present at least in the channel of each of the supports, and the supports have an average external size of 20 ?m or less.

Abstract: A polyimide resin composition containing a polyimide resin (A) and an amorphous resin (B), wherein the polyimide resin (A) contains a repeating structural unit represented by the following formula (1) and a repeating structural unit represented by the following formula (2), a content ratio of the repeating structural unit of the formula (1) with respect to the total of the repeating structural unit of the formula (1) and the repeating structural unit of the formula (2) is 20 to 70 mol %, and the amorphous resin (B) comprises a repeating structural unit represented by a predetermined formula (I), and a molded article containing the same: wherein R1 represents a divalent group having from 6 to 22 carbon atoms containing at least one alicyclic hydrocarbon structure; R2 represents a divalent chain aliphatic group having from 5 to 16 carbon atoms; and X1 and X2 each independently represent a tetravalent group having from 6 to 22 carbon atoms containing at least one aromatic ring.

Abstract: Provided is a vaccine for preventing and/or treating infection with human T-cell leukemia virus type 1 (HTLV-1). A lipid particle encapsulating a nucleic acid expressing a gp46 antigen or a Tax antigen of human T-cell leukemia virus type 1 (HTLV-1), wherein the lipid comprises a cationic lipid represented by general formula (Ia): or a pharmaceutically acceptable salt thereof, wherein R1 and R2 each independently represent a C1-C3 alkyl group; L1 represents a C17-C19 alkenyl group optionally having one or more C2-C4 alkanoyloxy groups; L2 represents a C10-C19 alkyl group optionally having one or more C2-C4 alkanoyloxy groups, or a C10-C19 alkenyl group optionally having one or more C2-C4 alkanoyloxy groups; and p is 3 or 4.

Abstract: A polyimide resin composition having a polyimide resin (A) and a polyether sulfone resin (B), wherein the polyimide resin (A) comprises a repeating structural unit of formula (1) and a repeating structural unit of formula (2), a content ratio of the repeating structural unit of the formula (1) with respect to the total of the repeating structural unit of the formula (1) and the repeating structural unit of the formula (2) is 20 to 70 mol %, and a mass ratio of the component (A) to the component (B), [(A)/(B)], is 0.1/99.9 to 65/35; and a molded article containing the same: where R1 represents a divalent group of 6 to 22 carbon atoms with an alicyclic hydrocarbon structure; R2 represents a divalent chain aliphatic group of 5 to 16 carbon atoms; and X1 and X2 each independently represent a tetravalent group of 6 to 22 carbon atoms and having an aromatic ring.

Abstract: As a technique enabling to simply and accurately diagnose human T cell leukemia virus type 1 (HTLV-1) related disease, there is provided a diagnostic method for an HTLV-1 related disease based on an amount of tumor necrosis factor receptor 2 (TNFR2) in a blood sample taken from a subject, wherein (1) it is determined based on an increase of the amount of TNFR2 that the subject suffers from, or is likely to develop, the HTLV-1 related disease; and/or (2) it is determined based on a decrease of the amount of TNFR2 that the subject is in remission, or is likely to be in remission, of the HTLV-1 related disease.

Abstract: As a technique enabling to simply and accurately diagnose human T cell leukemia virus type 1 (HTLV-1) related disease, there is provided a diagnostic method for an HTLV-1 related disease, comprising the steps of: measuring the amount of a marker protein in a blood sample taken from a subject, wherein the marker protein is at least one selected from the proteins listed in Tables 1 and 2; and, if a measured value is a predetermined reference value or more or the predetermined reference value or less, determining that the subject suffers from the HTLV-1 related disease or determining that the subject is in remission of the HTLV-1 related disease.